Anima Biotech is pioneering Translation Control Therapeutics, a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against undruggable proteins. With our proprietary technology that emits light pulses from ribosomes, we identify drug candidates that selectively decrease or increase the translation of proteins and elucidate their mechanism of action in a new target space. Our pipeline includes programs in Fibrosis (tissue selective Collagen I translation inhibitors), Oncology (selective translation inhibitors of c-Myc and K-Ras), RSV (viral translation inhibitors), Huntington's disease (translation inhibitors of the mutant protein without affecting the wild type, extendable to a many Repeat Associated Diseases) and our $1B partnership with Lilly around several Neuroscience targets. Our science was further validated with 7 patents, 15 peer-reviewed publications, and 17 scientific collaborations.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Collagen-I translation inhibitors
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):